Login to Your Account



OncoGenex: Third Phase III Starts with Clusterin Targeter

By Randy Osborne
BioWorld Today Contributing Writer

Monday, October 1, 2012
With fast-track status in hand for prostate cancer and two late-stage trials under way, OncoGenex Pharmaceuticals Inc.'s custirsen entered another Phase III study, this one in patients with non-small-cell lung cancer (NSCLC) whose disease has progressed despite chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription